[1] FDA. New Molecular Entity 2010 Statistics[EB/OL]. [2014-03-01].http://www.fda.gov/downloads/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/drugandbiologicapprov-alreports/ucm242695.pdf. [2] IMS. Top Corporation by Prescriptions Total RX in millions[EB/OL].(2011-04-07)[2014-03-01]. http://www.imshealth.com/deployedfiles/ims/Global/Content/Corporate/Press20Room/Top-line%20Market%20Data/2010%20Top-line%20Market%20Data/2010_Top_ Corporations_by_RX.pdf. [3] FDA .Facts about Generic Drugs [EB/OL]. (2012-09-19)[2014-03-01].http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/UnderstandingGenericDrugs/ucm167991.htm . [4] 唐健元,赵夏茵. 国外孤儿药管理制度对比研究及对我国的政策建议[J]. 中国新药杂志, 2013,22(14):1638-1642. [5] Marlene E. Haffner, Janet Whitley, Marie Moses.Two decades of orphan product development[J]. Nature Reviews Drug Discovery, 2002, 1(10): 821-825. [6] FDA. Pediatric Exclusivity Granted[EB/OL].(2014-02-05) [2014-03-01].http://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/ucm050005.htm. [7] 成殷,邵蓉. 美国儿科药品审批政策概述[J]. 中国执业药师,2012,9(05):43-46. [8] IMS. Top 20 Global Therapeutic Classes, 2010, Total Audited Markets[EB/OL]. [2014-03-01]. http://www.ims.com. [9] FDA. FY 2011: performance report to the president and congress for the Prescription Drug User Fee Act[EB/OL].(2012-03-01) [2014-03-01]. http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/UserFeeReports/PerformanceReports/PDUFA/UCM294101.pdf. [10] FDA. Guidance for Industry 180-Day Exclusivity When Multiple ANDAs Are Submitted on the Same Day[EB/OL]. (2003-07) [2014-03-01]. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072851.pdf. [11] Garth Boehm,姚立新,郑强. 企业付费法案与仿制药产业发展[J]. 中国新药杂志,2013,22(02):150-158. [12] Garth Boehm,姚立新,郑强. FDA公布2014财年仿制药企业付费修正案(GDUFA)付费标准[J]. 中国新药杂志,2013,22(18):2140-2141.